Glomerular filtration rate (GFR) \>=60 milliliter per minute (mL/min). The creatinine clearance (CrCl) estimated based on the Cockroft-Gault formula is used as a surrogate for the GFR
Effective contraception that is, barrier method (condoms, diaphragm), oral, injectable or implant birth control, for both male and female subjects during the whole trial period and for at least 6 months after the end of trial treatment, if the risk of conception exists
Recovered from relevant toxicities prior to inclusion in the trial
You may not be if
Previous exposure to Epidermal Growth Factor Receptor (EGFR)-targeting therapy
Previous chemotherapy for NSCLC; neo-adjuvant or adjuvant (radio-)chemotherapy is allowed if it was finished 6 months prior to start of trial treatment
Major surgery within 30 days prior to inclusion in the trial
Prior chest irradiation within 90 days prior to inclusion in the trial (palliative radiation of bone lesions is allowed)
Participation in another clinical trial or treatment with any investigational agent(s) within 30 days prior to inclusion in the trial
Concurrent chronic systemic immune therapy, chemotherapy for disease other than cancer, or hormone therapy for the treatment of cancer not indicated in the trial protocol
Superior vena cava syndrome contra-indicating hydration
Previous malignancy in the last 5 years except basal cell carcinoma of the skin or pre-invasive carcinoma of the cervix
Active infection (infection requiring intravenous antibiotics), including active tuberculosis, known and declared human immunodeficiency virus (HIV)
Myocardial infarction within 6 months prior to inclusion into the trial, uncontrolled congestive heart failure; or any current Grade 3 or 4 cardio-vascular disorder despite treatment
Known hypersensitivity reaction to any of the components of trial treatments
Symptomatic peripheral neuropathy National Cancer Institute-Common Toxicity Criteria (NCI-CTC) Grade \>= 2 and/or ototoxicity Grade \>= 2, except if due to trauma or mechanical impairment due to tumor mass
History of significant neurologic or psychiatric disorders including dementia, seizures, bipolar disorder
Medical or psychological condition that would not permit the subject to complete the trial or sign informed consent
Legal incapacity or limited legal capacity
Known drug abuse
Pregnancy (absence to be confirmed by serum beta-human chorionic gonadotropin \[beta-HCG test\]) or lactation period
Clareo Health | Trial With Cetuximab in Maintenance Therapy After Platinum Based Chemotherapy in First Line Treatment of Non-small Cell Lung Cancer (NSCLC)
